Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs worldwide, with company and product introduction, position in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market
Market status and development trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by types and applications
Cost and profit status of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market as:
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs worldwide, with company and product introduction, position in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market
Market status and development trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by types and applications
Cost and profit status of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market as:
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume, Revenue, Price and Gross Margin):
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
1.1 Definition of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in This Report
1.2 Commercial Types of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2.1 Preface
1.2.2 Eluxadoline
1.2.3 Alosetron
1.2.4 Rifaximin
1.2.5 Loperamide
1.2.6 Diphenoxylate + Atropine
1.2.7 Dicyclomine and Hyoscyamine
1.3 Downstream Application of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.5 Market Status and Trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2023
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2017
2.2 Sales Market of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.2.1 Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.2.2 Sales Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.3 Production Market of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.4 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2018-2023
2.4.1 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2018-2023
2.4.2 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
3.2 Sales Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
3.3 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry
4.2 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
5.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
5.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
5.1.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.1.4 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.1.5 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
5.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
5.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
5.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
5.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
6.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
6.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.4 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.5 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.7 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.8 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.9 Benelux Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
6.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
6.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
6.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
6.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
7.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
7.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.7 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
7.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
8.1.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.1.4 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.1.5 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
8.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
8.3.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
8.4 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
9.1.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
9.1.4 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
9.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
9.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.2 Production Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.3 Basic Information of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharmaceuticals
12.1.1 Company profile
12.1.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
12.2 Actavis
12.2.1 Company profile
12.2.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Actavis
12.3 Pfizer
12.3.1 Company profile
12.3.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.3.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.4 GlaxoSmithKline
12.4.1 Company profile
12.4.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.5 Salix Pharmaceuticals Ltd
12.5.1 Company profile
12.5.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
12.6 AstraZenenca
12.6.1 Company profile
12.6.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of AstraZenenca
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
13.1 Industry Chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
14.1 Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.2 Raw Materials Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.3 Labor Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.4 Manufacturing Expenses Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in This Report
1.2 Commercial Types of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2.1 Preface
1.2.2 Eluxadoline
1.2.3 Alosetron
1.2.4 Rifaximin
1.2.5 Loperamide
1.2.6 Diphenoxylate + Atropine
1.2.7 Dicyclomine and Hyoscyamine
1.3 Downstream Application of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.5 Market Status and Trend of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2023
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2013-2017
2.2 Sales Market of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.2.1 Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.2.2 Sales Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.3 Production Market of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
2.4 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2018-2023
2.4.1 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs 2018-2023
2.4.2 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
3.2 Sales Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
3.3 Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry
4.2 Global Market Forecast of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
5.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
5.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
5.1.3 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.1.4 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.1.5 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
5.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
5.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
5.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
5.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
5.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
6.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
6.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.4 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.5 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.7 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.8 Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.1.9 Benelux Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
6.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
6.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
6.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
6.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
6.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
7.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
7.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.1.7 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
7.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
7.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
8.1.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.1.4 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.1.5 Colombia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
8.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
8.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
8.3.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
8.4 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Countries
9.1.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
9.1.4 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status (2013-2017)
9.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Manufacturers
9.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.2 Production Value of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.3 Basic Information of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Astellas Pharmaceuticals
12.1.1 Company profile
12.1.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
12.2 Actavis
12.2.1 Company profile
12.2.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Actavis
12.3 Pfizer
12.3.1 Company profile
12.3.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.3.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.4 GlaxoSmithKline
12.4.1 Company profile
12.4.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.5 Salix Pharmaceuticals Ltd
12.5.1 Company profile
12.5.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
12.6 AstraZenenca
12.6.1 Company profile
12.6.2 Representative Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
12.6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin of AstraZenenca
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
13.1 Industry Chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) DRUGS
14.1 Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.2 Raw Materials Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.3 Labor Cost Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
14.4 Manufacturing Expenses Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
